Loading…

P740: IMPACT OF MAGROLIMAB IN COMBINATION WITH AZACITIDINE ON RED BLOOD CELLS IN PATIENTS WITH HIGHER‐RISK MYELODYSPLASTIC SYNDROME (HR MDS)

Saved in:

Bibliographic Details
Published in:	HemaSphere 2022-06, Vol.6, p.635-636
Main Authors:	Chen, J. Y., Johnson, L., McKenna, K. M., Choi, T. S., Duan, J., Feng, D., Tsai, J. M., Garcia‐Martin, N., Sompalli, K., Maute, R., Vyas, P., Majeti, R., Takimoto, C. H. M., Liu, J., Ramsingh, G., Chao, M. P., Volkmer, J.‐P., Weissman, I. L.
Format:	Article
Language:	English
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

cited_by
cites
container_end_page	636
container_issue
container_start_page	635
container_title	HemaSphere
container_volume	6
creator	Chen, J. Y. Johnson, L. McKenna, K. M. Choi, T. S. Duan, J. Feng, D. Tsai, J. M. Garcia‐Martin, N. Sompalli, K. Maute, R. Vyas, P. Majeti, R. Takimoto, C. H. M. Liu, J. Ramsingh, G. Chao, M. P. Volkmer, J.‐P. Weissman, I. L.
description
doi_str_mv	10.1097/01.HS9.0000845844.10159.58
format	article
fullrecord	<record><control><sourceid>wiley_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_4cd32e407e554cd2bebbf5cf621bb2d4</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_4cd32e407e554cd2bebbf5cf621bb2d4</doaj_id><sourcerecordid>HEM3BF03991</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2745-58ab05846997b045e6de5ef6bd41518591d1a021926152caceca57e49889ec2b3</originalsourceid><addsrcrecordid>eNqVkcFunDAURVHVSo3S_IPVVbtg-mxswNkxwAxWAY-AqppuLAOmmZSKCKaKsusXRPnGfkmdTNR227d5T1f3XMu6jvMWwwoDDz4AXmU1X4GdkLKQUitjxlcsfOGcERYQlxOKX_5zv3YuluXa-jHn3CfBmXO_CyhcIlHsorhBcoOKaFvJXBTRGokSxbJYizJqhCzRZ9FkKPoSxaIRiShTZLUqTdA6lzJBcZrn9SOys-60bOqTPxPbLK1-_XyoRP0RFfs0l8m-3uVR3YgY1fsyqWSRondZhYqkfv_GeTXocTEXz_vc-bRJmzhzc7kVcZS7HQkoc1moW7A_9jkPWqDM-L1hZvDbnmKGQ8ZxjzUQzImPGel0ZzrNAkN5GHLTkdY7d8Qpt5_0tbqZD9_1fKcmfVBPwjR_VXo-HrrRKNr1HjEUAsOYvUlr2nZg3eAT3Lakpzbr8pTVzdOyzGb4k4dBPRalACtblPpblHoqSrHQwvQE307j0czLt_HHrZnVldHj8UoBAUwp5i4BQsAH8FwA32MWi5-xw2ju_uNBlaWFt96Axzn2fgNXNJ5X</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>P740: IMPACT OF MAGROLIMAB IN COMBINATION WITH AZACITIDINE ON RED BLOOD CELLS IN PATIENTS WITH HIGHER‐RISK MYELODYSPLASTIC SYNDROME (HR MDS)</title><source>Wiley Open Access</source><source>PubMed Central</source><creator>Chen, J. Y. ; Johnson, L. ; McKenna, K. M. ; Choi, T. S. ; Duan, J. ; Feng, D. ; Tsai, J. M. ; Garcia‐Martin, N. ; Sompalli, K. ; Maute, R. ; Vyas, P. ; Majeti, R. ; Takimoto, C. H. M. ; Liu, J. ; Ramsingh, G. ; Chao, M. P. ; Volkmer, J.‐P. ; Weissman, I. L.</creator><creatorcontrib>Chen, J. Y. ; Johnson, L. ; McKenna, K. M. ; Choi, T. S. ; Duan, J. ; Feng, D. ; Tsai, J. M. ; Garcia‐Martin, N. ; Sompalli, K. ; Maute, R. ; Vyas, P. ; Majeti, R. ; Takimoto, C. H. M. ; Liu, J. ; Ramsingh, G. ; Chao, M. P. ; Volkmer, J.‐P. ; Weissman, I. L.</creatorcontrib><identifier>ISSN: 2572-9241</identifier><identifier>EISSN: 2572-9241</identifier><identifier>DOI: 10.1097/01.HS9.0000845844.10159.58</identifier><language>eng</language><publisher>Philadelphia, PA: Lippincott Williams & Wilkins</publisher><ispartof>HemaSphere, 2022-06, Vol.6, p.635-636</ispartof><rights>Copyright © 2022 The Author(s).</rights><rights>Lippincott Williams & Wilkins</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1097%2F01.HS9.0000845844.10159.58$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1097%2F01.HS9.0000845844.10159.58$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,11562,27924,27925,46052,46476</link.rule.ids></links><search><creatorcontrib>Chen, J. Y.</creatorcontrib><creatorcontrib>Johnson, L.</creatorcontrib><creatorcontrib>McKenna, K. M.</creatorcontrib><creatorcontrib>Choi, T. S.</creatorcontrib><creatorcontrib>Duan, J.</creatorcontrib><creatorcontrib>Feng, D.</creatorcontrib><creatorcontrib>Tsai, J. M.</creatorcontrib><creatorcontrib>Garcia‐Martin, N.</creatorcontrib><creatorcontrib>Sompalli, K.</creatorcontrib><creatorcontrib>Maute, R.</creatorcontrib><creatorcontrib>Vyas, P.</creatorcontrib><creatorcontrib>Majeti, R.</creatorcontrib><creatorcontrib>Takimoto, C. H. M.</creatorcontrib><creatorcontrib>Liu, J.</creatorcontrib><creatorcontrib>Ramsingh, G.</creatorcontrib><creatorcontrib>Chao, M. P.</creatorcontrib><creatorcontrib>Volkmer, J.‐P.</creatorcontrib><creatorcontrib>Weissman, I. L.</creatorcontrib><title>P740: IMPACT OF MAGROLIMAB IN COMBINATION WITH AZACITIDINE ON RED BLOOD CELLS IN PATIENTS WITH HIGHER‐RISK MYELODYSPLASTIC SYNDROME (HR MDS)</title><title>HemaSphere</title><issn>2572-9241</issn><issn>2572-9241</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>DOA</sourceid><recordid>eNqVkcFunDAURVHVSo3S_IPVVbtg-mxswNkxwAxWAY-AqppuLAOmmZSKCKaKsusXRPnGfkmdTNR227d5T1f3XMu6jvMWwwoDDz4AXmU1X4GdkLKQUitjxlcsfOGcERYQlxOKX_5zv3YuluXa-jHn3CfBmXO_CyhcIlHsorhBcoOKaFvJXBTRGokSxbJYizJqhCzRZ9FkKPoSxaIRiShTZLUqTdA6lzJBcZrn9SOys-60bOqTPxPbLK1-_XyoRP0RFfs0l8m-3uVR3YgY1fsyqWSRondZhYqkfv_GeTXocTEXz_vc-bRJmzhzc7kVcZS7HQkoc1moW7A_9jkPWqDM-L1hZvDbnmKGQ8ZxjzUQzImPGel0ZzrNAkN5GHLTkdY7d8Qpt5_0tbqZD9_1fKcmfVBPwjR_VXo-HrrRKNr1HjEUAsOYvUlr2nZg3eAT3Lakpzbr8pTVzdOyzGb4k4dBPRalACtblPpblHoqSrHQwvQE307j0czLt_HHrZnVldHj8UoBAUwp5i4BQsAH8FwA32MWi5-xw2ju_uNBlaWFt96Axzn2fgNXNJ5X</recordid><startdate>20220623</startdate><enddate>20220623</enddate><creator>Chen, J. Y.</creator><creator>Johnson, L.</creator><creator>McKenna, K. M.</creator><creator>Choi, T. S.</creator><creator>Duan, J.</creator><creator>Feng, D.</creator><creator>Tsai, J. M.</creator><creator>Garcia‐Martin, N.</creator><creator>Sompalli, K.</creator><creator>Maute, R.</creator><creator>Vyas, P.</creator><creator>Majeti, R.</creator><creator>Takimoto, C. H. M.</creator><creator>Liu, J.</creator><creator>Ramsingh, G.</creator><creator>Chao, M. P.</creator><creator>Volkmer, J.‐P.</creator><creator>Weissman, I. L.</creator><general>Lippincott Williams & Wilkins</general><general>Wiley</general><scope>24P</scope><scope>WIN</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>DOA</scope></search><sort><creationdate>20220623</creationdate><title>P740: IMPACT OF MAGROLIMAB IN COMBINATION WITH AZACITIDINE ON RED BLOOD CELLS IN PATIENTS WITH HIGHER‐RISK MYELODYSPLASTIC SYNDROME (HR MDS)</title><author>Chen, J. Y. ; Johnson, L. ; McKenna, K. M. ; Choi, T. S. ; Duan, J. ; Feng, D. ; Tsai, J. M. ; Garcia‐Martin, N. ; Sompalli, K. ; Maute, R. ; Vyas, P. ; Majeti, R. ; Takimoto, C. H. M. ; Liu, J. ; Ramsingh, G. ; Chao, M. P. ; Volkmer, J.‐P. ; Weissman, I. L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2745-58ab05846997b045e6de5ef6bd41518591d1a021926152caceca57e49889ec2b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chen, J. Y.</creatorcontrib><creatorcontrib>Johnson, L.</creatorcontrib><creatorcontrib>McKenna, K. M.</creatorcontrib><creatorcontrib>Choi, T. S.</creatorcontrib><creatorcontrib>Duan, J.</creatorcontrib><creatorcontrib>Feng, D.</creatorcontrib><creatorcontrib>Tsai, J. M.</creatorcontrib><creatorcontrib>Garcia‐Martin, N.</creatorcontrib><creatorcontrib>Sompalli, K.</creatorcontrib><creatorcontrib>Maute, R.</creatorcontrib><creatorcontrib>Vyas, P.</creatorcontrib><creatorcontrib>Majeti, R.</creatorcontrib><creatorcontrib>Takimoto, C. H. M.</creatorcontrib><creatorcontrib>Liu, J.</creatorcontrib><creatorcontrib>Ramsingh, G.</creatorcontrib><creatorcontrib>Chao, M. P.</creatorcontrib><creatorcontrib>Volkmer, J.‐P.</creatorcontrib><creatorcontrib>Weissman, I. L.</creatorcontrib><collection>Wiley Open Access</collection><collection>Wiley Free Archive</collection><collection>CrossRef</collection><collection>Directory of Open Access Journals</collection><jtitle>HemaSphere</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chen, J. Y.</au><au>Johnson, L.</au><au>McKenna, K. M.</au><au>Choi, T. S.</au><au>Duan, J.</au><au>Feng, D.</au><au>Tsai, J. M.</au><au>Garcia‐Martin, N.</au><au>Sompalli, K.</au><au>Maute, R.</au><au>Vyas, P.</au><au>Majeti, R.</au><au>Takimoto, C. H. M.</au><au>Liu, J.</au><au>Ramsingh, G.</au><au>Chao, M. P.</au><au>Volkmer, J.‐P.</au><au>Weissman, I. L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>P740: IMPACT OF MAGROLIMAB IN COMBINATION WITH AZACITIDINE ON RED BLOOD CELLS IN PATIENTS WITH HIGHER‐RISK MYELODYSPLASTIC SYNDROME (HR MDS)</atitle><jtitle>HemaSphere</jtitle><date>2022-06-23</date><risdate>2022</risdate><volume>6</volume><spage>635</spage><epage>636</epage><pages>635-636</pages><issn>2572-9241</issn><eissn>2572-9241</eissn><cop>Philadelphia, PA</cop><pub>Lippincott Williams & Wilkins</pub><doi>10.1097/01.HS9.0000845844.10159.58</doi><tpages>2</tpages><oa>free_for_read</oa></addata></record>
fulltext	fulltext
identifier	ISSN: 2572-9241
ispartof	HemaSphere, 2022-06, Vol.6, p.635-636
issn	2572-9241 2572-9241
language	eng
recordid	cdi_doaj_primary_oai_doaj_org_article_4cd32e407e554cd2bebbf5cf621bb2d4
source	Wiley Open Access; PubMed Central
title	P740: IMPACT OF MAGROLIMAB IN COMBINATION WITH AZACITIDINE ON RED BLOOD CELLS IN PATIENTS WITH HIGHER‐RISK MYELODYSPLASTIC SYNDROME (HR MDS)
url	http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T16%3A28%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wiley_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=P740:%20IMPACT%20OF%20MAGROLIMAB%20IN%20COMBINATION%20WITH%20AZACITIDINE%20ON%20RED%20BLOOD%20CELLS%20IN%20PATIENTS%20WITH%20HIGHER%E2%80%90RISK%20MYELODYSPLASTIC%20SYNDROME%20(HR%20MDS)&rft.jtitle=HemaSphere&rft.au=Chen,%20J.%20Y.&rft.date=2022-06-23&rft.volume=6&rft.spage=635&rft.epage=636&rft.pages=635-636&rft.issn=2572-9241&rft.eissn=2572-9241&rft_id=info:doi/10.1097/01.HS9.0000845844.10159.58&rft_dat=%3Cwiley_doaj_%3EHEM3BF03991%3C/wiley_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c2745-58ab05846997b045e6de5ef6bd41518591d1a021926152caceca57e49889ec2b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true